Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Thyroid Carcinoma, Anaplastic 2Adrenocortical Carcinoma 2Thyroid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × cemiplimab × Endocrine × Clear all
NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
12 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT06902376 2025-11-05

NEO-COMBATXL

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
12 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡